Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
Mais filtros










Intervalo de ano de publicação
1.
Food Chem ; 354: 129490, 2021 Aug 30.
Artigo em Inglês | MEDLINE | ID: mdl-33774531

RESUMO

Physico-chemical and sensory analysis of Iberian chorizo manufactured from three commercial categories raw material compiled in the current Spanish Iberian Quality standard (Black, Red; 100% Iberian and 50% Iberian × Duroc pigs, respectively, under Montanera, and White; 50% Iberian × Duroc pigs commercially fed) and packed under vacuum and modified atmosphere (MAP) were carried out, in order to address the influence of the genotype and animal production system and packaging on quality parameters, as well as the stability of these throughout long-term storage. Montanera categories showed higher values of γ-tocopherol, mono- and poly-unsaturated fatty acids, greater scores of flavour and taste and higher lipid oxidation during the whole storage. MAP preserved better colour, especially redness and lipid oxidative status. Iberian chorizo could attain a differentiated quality because of physico-chemical and sensorial characteristics derived from the Montanera that would be adequate preserved in both vacuum and MAP throughout long-term storage.


Assuntos
Embalagem de Alimentos/métodos , Produtos da Carne/análise , Animais , Atmosfera , Cromatografia Líquida de Alta Pressão , Cor , Ácidos Graxos Insaturados/análise , Peroxidação de Lipídeos , Refrigeração , Cloreto de Sódio/química , Suínos , Paladar/fisiologia , Vácuo , alfa-Tocoferol/análise , gama-Tocoferol/análise
3.
Leuk Res ; 39(8): 828-34, 2015 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-26009156

RESUMO

The impact of donor age in patients with acute myeloid leukemia and myelodysplastic syndrome who underwent allogeneic hematopoietic stem cell transplant (HSCT) remains unclear. In the current study, we evaluate 179 consecutive patients who received an HSCT, from January 2000 to January 2013, in our Institution. Most of the HSCT (91%) were HLA-matched. Patient and donor median age were 51 years (18-69) and 47 years (12-75) respectively, and 81 donors (45%) were older than 50 years. The median follow-up was 38 months (range 1-138), Kaplan-Meier estimated 3-year overall survival (OS) was 63% and disease free survival (DFS) was 56%. Interestingly, patients who received an HSCT from a donor older age (>50 y) showed a poorer OS (51% vs 73%; p=0.01), as well as a higher TRM (20% vs 8%; p=0.038) and higher relapse rate (28% vs 39%; p=0.03). In a stratified subanalysis, 3-year estimated OS was significantly lower among patients undergoing an HSCT from >50 years sibling donors compared to those receiving an HSCT from <50 years unrelated donor (54% vs 72%; p<0.001). In summary, we can conclude that receiving an HSCT from a donor over 50 years old is associated with poorer outcome in patients diagnosed with MDS and AML, and this information may be incorporated into the complex process of donor selection.


Assuntos
Transplante de Células-Tronco Hematopoéticas , Leucemia Mieloide Aguda/terapia , Síndromes Mielodisplásicas/terapia , Doadores não Relacionados/estatística & dados numéricos , Adolescente , Adulto , Fatores Etários , Idoso , Criança , Feminino , Transplante de Células-Tronco Hematopoéticas/mortalidade , Transplante de Células-Tronco Hematopoéticas/estatística & dados numéricos , Humanos , Leucemia Mieloide Aguda/mortalidade , Masculino , Pessoa de Meia-Idade , Síndromes Mielodisplásicas/mortalidade , Análise de Sobrevida , Transplante Homólogo , Resultado do Tratamento , Adulto Jovem
7.
SEMERGEN, Soc. Esp. Med. Rural Gen. (Ed. impr.) ; 37(6): 307-311, jun.-jul. 2011.
Artigo em Espanhol | IBECS | ID: ibc-89476

RESUMO

El avance en la medicina preventiva y predictiva aborda el estudio genético con el fin de identificar la presencia de genes que se asocian a patologías como el cáncer de mama y ovario, y cuya prevención y diagnóstico precoz guardan una clara relación con la supervivencia. La identificación de estos genes supone, por una parte, poder establecer medidas de prevención, pero también puede ser origen de conflictos ante las decisiones o perspectivas que plantean los resultados. En la siguiente revisión planteamos la manera en que los médicos de atención primaria y ginecólogos pueden orientar a la mujer en esta situación (AU)


The advances in preventive and predictive medicine has led to carrying out genetic studies with the purpose of identifying the presence of genes that are linked to diseases, such as breast and ovarian cancer, where prevention and early diagnosis are clearly connected to their survival. The identification of these genes means, on the one hand, that prevention measures can be established, but it also can be the origin of conflicts as regards the decisions or the future prospects arising from the results. In this review, we explain how primary care doctors and gynaecologists can guide women in this situation (AU)


Assuntos
Humanos , Feminino , Adulto , Pessoa de Meia-Idade , Neoplasias Ovarianas/diagnóstico , Neoplasias Ovarianas/prevenção & controle , Ovário/patologia , Medicina Preventiva/métodos , Neoplasias da Mama/epidemiologia , Neoplasias da Mama/prevenção & controle , Diagnóstico Precoce , Genes/genética , Medicina Preventiva/organização & administração , Medicina Preventiva/tendências
10.
Acta pediatr. esp ; 62(6): 254-256, jun. 2004. ilus
Artigo em Es | IBECS | ID: ibc-34043

RESUMO

Presentarnos un caso de neumonía por Mycoplasma pneumoniae en un paciente de seis años de edad. La sospecha diagnóstica se basó en la clínica y en las pruebas de imagen, confirmándose posteriormente con la serología. El propósito de este artículo es destacar que, dentro de la variabilidad de presentación radiológica de la neumonía por micoplasma, existe un patrón radiológico característico que debe orientar el diagnóstico hacia dicha entidad (AU)


Assuntos
Criança , Humanos , Mycoplasma pneumoniae , Pneumonia por Mycoplasma/microbiologia , Pneumonia por Mycoplasma , Pneumonia por Mycoplasma/tratamento farmacológico , Eritromicina/uso terapêutico , Doenças Pulmonares Intersticiais , Doenças Pulmonares Intersticiais/tratamento farmacológico , Doenças Pulmonares Intersticiais/microbiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...